埃穆里大学技术转让成功案例汇编
根据校方技术转让办提供的资料
Emory Products to Market
Surgical Instruments Specifically Designed for Off-pump Coronary Bypass
Skim through the Scanlan International surgical instrument catalog and John Puskas’s name emerges frequently: The Puskas micro-scissors, long and slender, with angled fine blades. The Never Shear Dual Guide titanium forceps, “design developed in cooperation with John D. Puskas.” The Scanlan Puskas ?Black Knight? Lillehei-Potts Scissors.
These medical devices started out as custom instruments for cardiac surgeon John Puskas, MD, professor of thoracic surgery at Emory’s School of Medicine, to use in his pioneering off-pump coronary artery bypass surgeries, in which the surgeon operates on a heart still beating within the chest. Puskas’ company Innovative Cardiac Technologies (“ICT”) has licensed these instruments from Emory and sells them through Scanlan International, resulting in regular royalties to Puskas and Emory.
[url=javascript:return false;]Read more ?[/url]
“When you’ve got the heart beating, bleeding, and in relatively correct anatomic position, you operate deeper in the chest, which made the traditional instruments a lot less user friendly,” Puskas says. “These instruments are long and slim and have different contours to them. We’ve created a whole set of them.” Some of the tools’ features are unique and patentable. “We just got notification from patent attorney that claims are allowed for the forceps,” Puskas says.
As the popularity of off-pump bypass surgery has spread, so has the demand for a set of instruments designed specifically for beating-heart surgery. “We use them all the time at Emory,” Puskas says. “I just used them last night during emergency surgery. In fact, I tried to make them gold and blue, so they’d be Emory colors, but when you make titanium gold it doesn’t stay constant through multiple autoclavings. So we had to make them grey/silver instead.”
Traditional bypass surgery, which has been the standard for more than four decades, involves operating on an arrested heart, with the patient hooked up to a heart and lung machine while the heart is still, drained of blood, and pulled partly out of the chest. “When the heart is empty, flaccid, and not moving, you can literally pick it up with gloves and operate with relatively short instruments.”
Another advantage of the longer, slimmer, angled tools is that both the surgeon and residents can see what is happening in the chest cavity, as opposed to attempting to peer around each other’s hands, facilitating training.
“This is the advantage of surgeon-designed tools,” Puskas says. “Surgeons are, first and foremost, surgeons. We know what we need and how it should work.”
Discovery of HIV Antiretroviral Drugs Led to Largest University Royalty Deal in History
More than 80 percent of people who have HIV take at least one of the drugs invented by Emory professors Ray Schinazi, Dennis Liotta, and researcher Woo-Baeg Choi, PhDs.
In the early 1990s, Schinazi, an infectious disease and antiviral expert, Liotta, a chemist, and Choi announced the discovery of an unusual molecule, FTC (emtricitabine, sold alone as Emtriva®, with the “Em” standing for Emory) and a chemically similar compound, 3TC (lamivudine, sold alone as Epvir®). Both drugs are in the class known as nucleoside reverse transcriptase inhibitors, which works against the enzyme that copies HIV RNA into new viral DNA.
[url=javascript:return false;]Read more ?[/url]
“Everyone was intrigued but skeptical about our work—no one realized the importance of what we had found,” Schinazi says. The two were determined however, and applied for grants that enabled further research. “We pushed Emory University very hard file patent applications to protect these inventions (FTC and 3TC). Emory finally did, and received the rewards less than ten years later.”
These rewards, in fact, ultimately would include a $540 million deal, the largest royalty sale in the history of higher education.
FTC was licensed in 1996 to Triangle Pharmaceuticals, a biotech company founded by Schinazi in 1995. In 1999 and again in 2002, Emory resolved patent disputes with various third parties to consolidate intellectual property rights and thereby clear the path to market for FTC. In 2003, Gilead acquired Triangle for $482 million and in the same year, FTC was approved by the FDA. Shire and GlaxoSmithKline jointly licensed Emory’s patents related to 3TC, which drug is contained in at least 5 products.
In 2005, Gilead Sciences and Royalty Pharma signed a deal with Emory to buy its royalty interest for FTC for $525 million. Gilead paid Emory an additional $15 million to alter the terms of the license as it relates to the company’s plans for developing the compound for use against another disease. 8 1 2 3 4 5 6 下一页 尾页
根据校方技术转让办提供的资料
Emory Products to Market
Surgical Instruments Specifically Designed for Off-pump Coronary Bypass
Skim through the Scanlan International surgical instrument catalog and John Puskas’s name emerges frequently: The Puskas micro-scissors, long and slender, with angled fine blades. The Never Shear Dual Guide titanium forceps, “design developed in cooperation with John D. Puskas.” The Scanlan Puskas ?Black Knight? Lillehei-Potts Scissors.
These medical devices started out as custom instruments for cardiac surgeon John Puskas, MD, professor of thoracic surgery at Emory’s School of Medicine, to use in his pioneering off-pump coronary artery bypass surgeries, in which the surgeon operates on a heart still beating within the chest. Puskas’ company Innovative Cardiac Technologies (“ICT”) has licensed these instruments from Emory and sells them through Scanlan International, resulting in regular royalties to Puskas and Emory.
[url=javascript:return false;]Read more ?[/url]
“When you’ve got the heart beating, bleeding, and in relatively correct anatomic position, you operate deeper in the chest, which made the traditional instruments a lot less user friendly,” Puskas says. “These instruments are long and slim and have different contours to them. We’ve created a whole set of them.” Some of the tools’ features are unique and patentable. “We just got notification from patent attorney that claims are allowed for the forceps,” Puskas says.
As the popularity of off-pump bypass surgery has spread, so has the demand for a set of instruments designed specifically for beating-heart surgery. “We use them all the time at Emory,” Puskas says. “I just used them last night during emergency surgery. In fact, I tried to make them gold and blue, so they’d be Emory colors, but when you make titanium gold it doesn’t stay constant through multiple autoclavings. So we had to make them grey/silver instead.”
Traditional bypass surgery, which has been the standard for more than four decades, involves operating on an arrested heart, with the patient hooked up to a heart and lung machine while the heart is still, drained of blood, and pulled partly out of the chest. “When the heart is empty, flaccid, and not moving, you can literally pick it up with gloves and operate with relatively short instruments.”
Another advantage of the longer, slimmer, angled tools is that both the surgeon and residents can see what is happening in the chest cavity, as opposed to attempting to peer around each other’s hands, facilitating training.
“This is the advantage of surgeon-designed tools,” Puskas says. “Surgeons are, first and foremost, surgeons. We know what we need and how it should work.”
Discovery of HIV Antiretroviral Drugs Led to Largest University Royalty Deal in History
More than 80 percent of people who have HIV take at least one of the drugs invented by Emory professors Ray Schinazi, Dennis Liotta, and researcher Woo-Baeg Choi, PhDs.
In the early 1990s, Schinazi, an infectious disease and antiviral expert, Liotta, a chemist, and Choi announced the discovery of an unusual molecule, FTC (emtricitabine, sold alone as Emtriva®, with the “Em” standing for Emory) and a chemically similar compound, 3TC (lamivudine, sold alone as Epvir®). Both drugs are in the class known as nucleoside reverse transcriptase inhibitors, which works against the enzyme that copies HIV RNA into new viral DNA.
[url=javascript:return false;]Read more ?[/url]
“Everyone was intrigued but skeptical about our work—no one realized the importance of what we had found,” Schinazi says. The two were determined however, and applied for grants that enabled further research. “We pushed Emory University very hard file patent applications to protect these inventions (FTC and 3TC). Emory finally did, and received the rewards less than ten years later.”
These rewards, in fact, ultimately would include a $540 million deal, the largest royalty sale in the history of higher education.
FTC was licensed in 1996 to Triangle Pharmaceuticals, a biotech company founded by Schinazi in 1995. In 1999 and again in 2002, Emory resolved patent disputes with various third parties to consolidate intellectual property rights and thereby clear the path to market for FTC. In 2003, Gilead acquired Triangle for $482 million and in the same year, FTC was approved by the FDA. Shire and GlaxoSmithKline jointly licensed Emory’s patents related to 3TC, which drug is contained in at least 5 products.
In 2005, Gilead Sciences and Royalty Pharma signed a deal with Emory to buy its royalty interest for FTC for $525 million. Gilead paid Emory an additional $15 million to alter the terms of the license as it relates to the company’s plans for developing the compound for use against another disease. 8 1 2 3 4 5 6 下一页 尾页